The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...

GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. ...

Eli Lilly and Co. announced Wednesday that it will boost its investment in Lebanon to more than $13 billion. The move increases Lilly's capital commitment in the United States to more than $23 billion ...

NHS England plans a phased rollout of tirzepatide to treat severe obesity, with early trials showing significant weight loss.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

This week, the FDA granted approval to Sanofi SNY and Regeneron’s REGN blockbuster drug, Dupixent, for its sixth indication.

The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...

The state of Texas has filed a lawsuit against drug companies that produce insulin and pharmacy benefit managers (PBM), claiming there is a conspiracy to k ...

Texas is suing insulin manufacturers and PBMs, including Eli Lilly and CVS Pharmacy, alleging a scheme to hike insulin prices ...

Artificial intelligence is quickly becoming a valuable tool in the U.S. healthcare industry. Experts say a thoughtful ...

Texas Attorney General Ken Paxton has filed a lawsuit against major insulin manufacturers and pharmacy benefit managers over an alleged conspiracy to increase i ...